================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------
FORM 12b-25
Notification of Late Filing
----------
[ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-QSB [ ] Form N-SAR
For Quarter Ended: March 31, 2002
Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
N/A
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
--------------------------------------------------------------------------------
Fountain Pharmaceuticals, Inc.
-------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
505 S. Westland Avenue, Suite D
Tampa, FL 33606
-------------------------------------
(Address of Principal Executive Office)
================================================================================
--------------------------------------------------------------------------------
PART II - RULES 12B-25 (B) AND (C)
--------------------------------------------------------------------------------
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report or semi-annual report/portion
thereof will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly
report/portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
--------------------------------------------------------------------------------
PART III - NARRATIVE
--------------------------------------------------------------------------------
State below in reasonable detail the reasons why the Form 10-KSB, 11-K, 20-F,
10-QSB or N-SAR or portion thereof could not be filed within the prescribed
time:
The Company's limited resources were consumed by management's efforts
to make an acquisition, the closing of which has temporarily been
postponed. Due to this reason, the Company was unable to complete this
filing on a timely basis without unreasonable effort and expense.
--------------------------------------------------------------------------------
PART IV - OTHER INFORMATION
--------------------------------------------------------------------------------
(1) Name and telephone number of person to contact in regard to this
notification
Joel C. Schneider, Esq. (516) 228-8181
(2) Have all other periodic reports required (under Section 13 or 15(d) of
the Securities and Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940) during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports)
been filed? If answer no, identify report(s).
[X] YES [ ] NO
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statement to be included in the subject
report or portion thereof?
[X] YES [ ] NO
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and; if appropriate, state the reasons
why a reasonable estimate of the results can not be made.
A qualitative and quantitative statement cannot be provided at
this time, for reasons set forth in Part III above.
Fountain Pharmaceuticals, Inc. has caused this notification to be
signed on its behalf by the undersigned thereunto duly authorized.
Dated: May 15, 2002 Fountain Pharmaceuticals, Inc.
By: /s/ Brendon K. Rennert
-------------------------------
Brendon K. Rennert, President
--------------------------------------------------------------------------------
ATTENTION
Intentional misstatements or omissions of act constitute
Federal Criminal Violations (See 18 U.S.C. 1001).
--------------------------------------------------------------------------------